Monoclonal Gammopathy of Undetermined Significance
A premalignant condition defined by a serum paraprotein <30 g/L, bone marrow plasma cells <10%, and absence of myeloma-related organ damage (CRAB criteria). Progresses to myeloma or related malignancy at approximately 1% per year.
Key Facts
Diagnostic criteria: paraprotein <30 g/L, bone marrow clonal plasma cells <10%, no CRAB criteria (Calcium elevation, Renal insufficiency, Anaemia, Bone lesions) Prevalence: ~3–4% of the general population aged >50 years; increases with age Progression rate: ~1% per year to multiple myeloma, Waldenström's, AL amyloidosis, or lymphoproliferative disorder Risk stratification: Mayo Clinic model uses paraprotein level, type (non-IgG higher risk), and abnormal FLC ratio High-risk MGUS: IgM type, paraprotein >15 g/L, abnormal FLC ratio — 20-year progression risk ~58% Monitoring: serum protein electrophoresis and FBC every 3–6 months for first year, then annually if stable No treatment required — watchful waiting with regular monitoring Smouldering myeloma is an intermediate stage between MGUS and myeloma (paraprotein ≥30 g/L or plasma cells 10–59%, no CRAB)
Overview
Key Facts
MGUS is the most common plasma cell disorder. It is considered a precursor condition to multiple myeloma and other lymphoproliferative disorders. Most patients with MGUS will never progress, but lifelong monitoring is recommended.
Epidemiology
- Prevalence: 3–4% in adults >50 years, rising to >5% in those >70 years
- More common in males and African Americans (2–3× higher prevalence)
- Approximately 60% of myeloma patients had a preceding MGUS
- Most common incidental finding on serum protein electrophoresis
Aetiology
- Arises from a clonal population of plasma cells (or B-lymphocytes in IgM MGUS)
- Genetic predisposition: first-degree relatives have 2–3× increased risk
- Environmental factors: pesticides, radiation exposure (modest associations)
- IgG MGUS (~70%), IgM (~15%), IgA (~12%), biclonal (~3%)
Pathophysiology
- Initiating genetic events (e.g. IgH translocations, trisomies) create a clonal plasma cell population
- The clone produces monoclonal immunoglobulin (paraprotein/M-protein)
- In MGUS, the clone is small and stable, without end-organ damage
- Progression to myeloma requires additional genetic hits (e.g. MYC translocations, del(17p), gain(1q))
- IgM MGUS originates from lymphoplasmacytic cells and may progress to Waldenström's macroglobulinaemia rather than myeloma
Clinical Presentation
Typical Presentation
- Usually asymptomatic — discovered incidentally on blood tests
- Elevated ESR or total protein on routine bloods
- Found during investigation of other conditions
Associations
- Peripheral neuropathy (especially IgM MGUS — anti-MAG antibodies)
- Osteoporosis (increased osteoclast activity)
- Increased infection risk (relative immunoparesis)
Red Flags (suggest progression to myeloma)
- New-onset bone pain (especially back pain)
- Unexplained anaemia (Hb <100 g/L)
- Hypercalcaemia
- Rising creatinine
- Rapidly rising paraprotein (>25% increase)
- New soft tissue plasmacytoma
- Heavy proteinuria (light chain cast nephropathy or AL amyloidosis)
Differential Diagnosis
| Diagnosis | Key Features | Investigation |
|---|---|---|
| Multiple myeloma | CRAB criteria, paraprotein often >30 g/L, plasma cells ≥10% | SPEP, FLC, bone marrow, imaging |
| Smouldering myeloma | Paraprotein ≥30 g/L or plasma cells 10–59%, no CRAB | SPEP, FLC, bone marrow, PET-CT |
| Waldenström's macroglobulinaemia | IgM paraprotein, lymphoplasmacytic infiltrate, hyperviscosity | IgM level, bone marrow, MYD88 mutation |
| AL amyloidosis | Organ deposition (heart, kidney, nerve), Congo red positive | Tissue biopsy, FLC, SAP scan |
| CLL/lymphoma | Lymphocytosis, lymphadenopathy | FBC, flow cytometry, CT |
| Reactive plasmacytosis | Chronic infection, autoimmune disease, polyclonal increase | Immunofixation (polyclonal pattern) |
Diagnosis / Investigation
Bedside
- Clinical examination: no specific findings expected
Bloods
- Serum protein electrophoresis (SPEP): quantify paraprotein level
- Serum immunofixation: confirm monoclonal band and identify heavy/light chain type
- Serum free light chains (FLC): kappa:lambda ratio (abnormal suggests clonality)
- FBC: exclude anaemia (Hb <100 suggests progression)
- U&Es, calcium: exclude CRAB criteria
- LDH, beta-2 microglobulin: prognostic markers
- Immunoglobulin levels: quantitative Ig (immunoparesis = suppression of uninvolved Ig classes)
Imaging
- Not routinely required for MGUS unless symptoms suggest myeloma
- If progression suspected: whole-body low-dose CT (replaces skeletal survey per NICE NG35) or PET-CT
Special Tests
- Bone marrow biopsy: if paraprotein >15 g/L, non-IgG type, abnormal FLC ratio, or symptoms suggesting progression
- Urine Bence Jones protein: 24-hour urine or urine immunofixation
- FISH/cytogenetics: on bone marrow if performed (risk stratification)
Management
Non-pharmacological
- Watchful waiting: no treatment for MGUS
- Patient education: symptoms of progression (bone pain, fatigue, infections, weight loss)
- Monitoring schedule: SPEP, FBC, calcium, renal function every 3–6 months for first year, then annually if stable
- Risk-adapted monitoring: low-risk MGUS may be monitored in primary care; high-risk in secondary care
Pharmacological
- No treatment indicated for MGUS
- Treat associated conditions: peripheral neuropathy (gabapentin/pregabalin), osteoporosis (bisphosphonates if indicated)
- Vaccination: annual influenza, pneumococcal vaccination (immune suppression risk)
Surgical/Interventional
- Not applicable
Referral Criteria
- Haematology referral: all newly diagnosed MGUS for initial assessment and risk stratification
- Urgent referral: if CRAB criteria develop (suspected myeloma) — refer via NICE NG35 suspected cancer pathway
- Re-referral: rising paraprotein, new symptoms, new cytopenias
- GP follow-up: low-risk MGUS can be monitored in primary care after initial haematology assessment
Prognosis
- Overall progression rate: ~1% per year (lifetime risk)
- Low-risk MGUS (IgG, paraprotein <15 g/L, normal FLC ratio): 20-year progression risk ~5%
- High-risk MGUS (non-IgG, paraprotein >15 g/L, abnormal FLC ratio): 20-year progression risk ~58%
- Most patients die of unrelated causes — MGUS alone does not reduce life expectancy significantly
- IgM MGUS: higher risk of progression to Waldenström's or lymphoma
- Light chain MGUS: lower progression risk (~0.3% per year)
- Regular monitoring allows early detection of progression when treatment is most effective
Other Relevant Information
Mayo Clinic MGUS Risk Stratification
| Risk Factor | Present |
|---|---|
| Non-IgG isotype | Yes/No |
| Paraprotein >15 g/L | Yes/No |
| Abnormal FLC ratio (<0.26 or >1.65) | Yes/No |
| Risk Group | Number of Factors | 20-Year Progression Risk |
|---|---|---|
| Low | 0 | 5% |
| Low-intermediate | 1 | 21% |
| High-intermediate | 2 | 37% |
| High | 3 | 58% |
MGUS vs Smouldering Myeloma vs Myeloma
| Feature | MGUS | Smouldering Myeloma | Multiple Myeloma |
|---|---|---|---|
| Paraprotein | <30 g/L | ≥30 g/L | Any level |
| BM plasma cells | <10% | 10–59% | ≥10% |
| End-organ damage | None | None | CRAB or SLiM criteria |
| Treatment | Monitoring | Monitoring (or trial) | Chemotherapy |